TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework to help clinicians prescribe obesity medications to older adults with attention to function, nutrition and individual priorities. The paper applies the Geriatrics 5Ms and recommends pretreatment assessment and supportive measures such as resistance training and adequate protein intake.
The American Geriatrics Society (AGS) has released a case-based framework for clinicians prescribing obesity medications to older adults, including GLP-1 medicines. Published in the Journal of the American Geriatrics Society, the paper calls for assessments of function, nutrition and cognition before treatment, reflecting concerns about frailty, muscle loss and other age-related factors.
Developed by the AGS Healthy Aging Special Interest Group, the paper applies the society’s Geriatrics 5Ms Framework to incretin therapies. The five areas are Mind, Mobility, Medications, Multicomplexity and Matters Most. Organizing prescribing decisions around those domains is intended to help clinicians weigh a medication’s potential benefits against an older person’s health status, daily functioning and priorities.
The authors recommend assessing functional status, nutritional adequacy and cognitive impairment before treatment. They also highlight possible concerns including sarcopenia and frailty, loss of lean muscle, malnutrition and dehydration. These are considerations for clinicians to evaluate, not outcomes the paper says will occur in every patient.
The framework recommends pairing medication treatment with supportive measures, including resistance training and adequate dietary protein. For some patients, it says, care may involve a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The report describes this as a practical approach rather than a single prescribing plan for all older adults.
Prescribing Beyond Weight Loss
The framework matters because it places function, nutrition and personal priorities alongside weight management when clinicians consider obesity medicines for older patients. A treatment decision that focuses on weight alone may not capture concerns such as maintaining mobility or avoiding inadequate nutrition. The 5Ms offer a structure for raising those issues during care discussions.
The paper also addresses an evidence gap: older adults are underrepresented in clinical trials of these medicines, according to the source report. That underrepresentation limits how confidently trial findings can be applied to every older patient. The framework does not resolve that gap, but it identifies age-related factors clinicians should account for when making individual decisions.
Its proposed co-interventions also underline that prescribing can involve more than a medication choice. Nutrition and strength-focused activity may need attention alongside treatment, with additional professionals involved when appropriate. The report does not claim that these measures eliminate medication risks or guarantee a particular outcome.
Popular right now
Dyson V8 Cyclone Cordless Vacuum
Ninja DualZone 6-in-1 Air Fryer, 8-Qt, Grey, DZ801
Dyson Airwrap i.d. Multi-Styler for Straight and Wavy Hair
As an affiliate, we earn on qualifying purchases.
The Geriatrics 5Ms in Practice
The new paper focuses on incretin therapies, a category that includes GLP-1 medications acting through gut-derived hormonal pathways. The source report says these medicines may offer benefits for weight management, glycemic control and other health conditions. It does not provide drug-specific prescribing instructions, comparative results or treatment recommendations for particular diagnoses.
Instead, the authors use case-based discussion to show how the 5Ms framework can inform decisions. Mind covers cognition; Mobility considers movement and function; Medications places a new prescription among a patient’s other medicines; Multicomplexity accounts for interacting health needs; and Matters Most centers the patient’s goals. The framework’s emphasis is on applying those considerations to the person rather than assuming older adults share the same risks or priorities.
The report identifies the article as Elias M. Wisdom and colleagues’ “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing,” published in the Journal of the American Geriatrics Society in 2026. Its DOI is 10.1111/jgs.70769.
“Safe prescribing requires pretreatment assessment of functional status, nutritional adequacy and cognitive impairment.”
— The AGS paper, as summarized by Medical Xpress
Evidence and Individual Risks
The source report does not specify how many older adults were represented in the clinical trials, or quantify the risks of muscle loss, malnutrition or dehydration for particular drugs. It also does not give medication-specific dosing guidance, define which patients should or should not receive treatment, or report new clinical outcome data from the framework itself. Those details should not be inferred from the paper’s general recommendations.
It remains unclear from the available material how clinicians will put the framework into practice across different care settings, or whether subsequent research will measure its effects on prescribing and patient outcomes. The paper offers an approach for clinical decision-making; it is not presented as a clinical trial demonstrating that the framework improves outcomes. Treatment decisions are individual medical decisions and should be discussed with a qualified health professional.
Applying the Framework in Care
The paper’s next step is practical application: clinicians can use its cases and the 5Ms structure when discussing obesity medicines with older adults. The source material does not announce a rollout, implementation deadline or scheduled follow-up study. It also gives no timeline for updated guidance.
For patients and care teams, the framework points toward conversations about baseline function, nutritional needs, cognition, other medications and the patient’s own goals before a prescription is considered. Where suitable, clinicians may also discuss strength training, protein intake and team-based support. How widely the approach is adopted, and what evidence emerges about its effects, remain open questions.
Key Questions
What did the American Geriatrics Society publish?
The AGS released a case-based framework for clinicians prescribing obesity medicines to older adults. The paper applies the Geriatrics 5Ms to incretin therapy and discusses age-related factors relevant to care.
What should clinicians assess before treatment?
The paper emphasizes pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. It also calls attention to frailty, sarcopenia, lean muscle loss, malnutrition and dehydration as considerations.
Does the framework recommend support alongside medication?
Yes. It recommends considering resistance training and adequate dietary protein alongside treatment. Some older adults may benefit from a team that includes nutrition, physical therapy, fitness or behavioral health professionals.
Does the paper prove these medicines are safe for all older adults?
No. The report describes a prescribing framework, not evidence that any obesity medicine is safe or appropriate for every older adult. The source notes that older adults are underrepresented in clinical trials, and decisions should be made with a qualified clinician.
Source: medicalxpress.com
